USFDA issues two observations at Dr. Reddy's Mexico API facility

Regulatory & Legal View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹1165.50

prior close

₹1163.70

announcement price

After-mkt

timing

Nifty 100market-1.4%-0.3% vs market

Pharmaceuticals peers, median of 172sector-1.9%+0.1% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty 100 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-1.4-0.3-1.9+0.1

Next day

-2.2-1.1-1.1-2.1-0.1

+0.8-0.7+1.5-1.2+2.0

+1.7-0.2+1.9-0.4+2.1

+3.1+0.1+3.1+0.2+2.9

+3.6-0.3+3.9-0.1+3.7

+3.0-1.3+4.3-0.2+3.2

15d

+3.1-3.5+6.5-3.1+6.1

+4.6-2.3+6.9-6.0+10.6

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA completed a records assessment at Dr. Reddy's API facility Industrias Químicas Falcón de México in Jiutepec, Morelos, between July 17 and September 8, 2026. The inspection concluded with a Form FDA 2953 containing two observations. The company will respond to these observations within the stipulated timeline.

Likely market impact

Two USFDA observations are common in inspections but can signal compliance gaps. Watch for company response details and any escalation risk.